Clinical Trial
Atacama Therapeutics is conducting a randomized, placebo controlled twelve-week Phase 2 Acne Clinical trial for approximately 100 participants. Participants will receive either oral AT-5214 or placebo tablets, 4 mg twice daily (BID). Investigator global assessment (IGS) of acne severity will be conducted at Screening, Week 4, Week 8, and Week 12 post-baseline. The primary end point for the study will be the absolute change from baseline in mean IGA score in each treatment group at Week 12 post-baseline (end of treatment). AT-5214 has been shown to significantly reduce facial sebum production in previous Phase 2 trials.
Additional Information on the Phase 2 Acne Trial
St George's Sydney
Dr. Esther Hong - FACD
Dr. Esther Hong is a highly regarded general Dermatologist with a breadth of experience across Sydney.
Dr. Hong has special interest and experience in skin cancer detection and treatment, psoriasis, eczema, acne, paediatric and vulval dermatology, as well as cosmetic dermatology and axillary hyperhidrosis.
She has extensive experience working in research and clinical dermatology across New South Wales as a Staff Specialist at Royal North Shore Hospital and private practices across Sydney. She is a member of the Northern Sydney Health District Human Research Ethics Committee and has recently been involved in exploring holistic patient support in psoriasis. She is a dedicated member of the College of Dermatology as mentor and lecturer at UNSW School of Medicine. Learn more.
St Vincent’s Melbourne
Dr Benjamin Daniel - Mmed (Clin Epi) (Hons), MBBS, BA, Bcom, FACD
Dr Benjamin Daniel is a fellow of the Australasian College of Dermatologists, a consultant Dermatologist at St Vincentʼs Hospital and the Western Hospital.
He did a 2 year pre-dermatology research fellowship in autoimmune blistering diseases alongside his masters of medicine for which he received honours for his thesis. During his dermatology training he has worked at various hospitals in Melbourne including the Alfred Hospital, Victorian Melanoma Service, Peter MacCallum Cancer Hospital and the Royal Childrenʼs Hospital, as well as the National Skin Centre in Singapore.
Dr Daniel has published several articles in peer reviewed journals and presented at both local and international conferences. He has also written book chapters on common skin conditions. He was awarded the Harvey Rotstein Award for academic excellence, collegiality and professionalism through the registrar training. He has a particular interest in eczema, psoriasis, acne, autoimmune blistering diseases, pigment disorders and skin cancer management.Learn more.